Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.52 |
| ▸ | MMP9 | P14780 | 6/20 | 0.52 |
| ▸ | MMP14 | P50281 | 3/20 | 0.47 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | PARL | Q9H300 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 3/20 | 0.44 |
| ▸ | MMP12 | P39900 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | MMP16 | P51512 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005594 | 0.92 | MMP2 (0.51) | MMP2MMP9MMP14MMP7PARL | |
| SCHEMBL2004234 | 0.91 | MMP2 (0.50) | MMP2MMP9MMP14MMP7PARL | |
| SCHEMBL2013112 | 0.82 | MMP9 (0.49) | MMP2MMP9MMP14MMP7PARL | |
| SCHEMBL2009394 | 0.81 | MMP9 (0.51) | MMP2MMP9MMP14MMP7PARL | |
| SCHEMBL2009256 | 0.79 | CA1 (0.51) | MMP2MMP9CA12CA1CA2 | |
| SCHEMBL2009361 | 0.78 | MEP1B (0.41) | MMP2MMP9MMP14MMP7MMP1 | |
| SCHEMBL2009054 | 0.78 | CA2 (0.46) | MMP2MMP9MMP14MMP7CA12 | |
| SCHEMBL2013462 | 0.78 | LMNA (0.42) | MMP2MMP9CA12CA1CA2 | |
| SCHEMBL2002405 | 0.78 | MMP2 (0.56) | MMP2MMP9MMP14MMP7PARL | |
| SCHEMBL2006223 | 0.78 | POLB (0.43) | MMP2MMP9MMP14MMP7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964643-B2 | Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-1756046-B1 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| EP-1756046-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118528-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | ARSA, CNKSR1, BCL9L | MMP2 1086/4885MMP9 1159/4885MMP14 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.